2009-05-08 15:27:01 -

NeuroMetrix, Inc. (Nasdaq: NURO), a health care company transforming patient care through neurotechnology, today announced that the Compensation Committee of NeuroMetrix's Board of Directors granted of an inducement stock option to purchase up to 100,000 shares of common stock to Walter Christensen, its newly appointed Senior Vice President, Global Sales, on May 4, 2009.

The stock option is a non-qualified stock

option and has an exercise price per share equal to $1.73, the fair market value of the underlying shares as of the grant date. The option vests as to 25% of the underlying shares on the first anniversary of the grant date and as to 1/16 of the underlying shares quarterly thereafter, so as to be 100% vested on the fourth anniversary of the grant date, subject to Mr.
Christensen's continued service to NeuroMetrix. The stock option has a maximum term of ten (10) years.

The stock option was granted as an inducement material to Mr.

Christensen’s entering into employment with NeuroMetrix in accordance with NASDAQ Listing Rule 5635(c)(4).

About NeuroMetrix


NeuroMetrix is a science-based healthcare company transforming patient care through neurotechnology. To date, our focus has been primarily on the assessment of neuropathies. Neuropathies affect the peripheral nerves and parts of the spine and are frequently caused by or associated with carpal tunnel syndrome, diabetes, sciatica, and other clinical disorders. We market systems for the performance of nerve conduction studies and needle electromyography procedures. Our product pipeline includes a system designed to deliver pharmacologic agents such as anesthetics and corticosteroids in close proximity to nerves for regional anesthesia, pain control and the treatment of focal neuropathies. We are also developing neurostimulation-based devices that promote nerve fiber regeneration in acute peripheral nerve and spinal cord injuries. For more information, visit www.neurometrix.com : .



NeuroMetrix, Inc.Joseph A. Calo, 781-314-2775Acting Chief
Financial Officer neurometrix.ir@neurometrix.com : mailto:neurometrix.ir@neurometrix.com